Cargando…
Tocilizumab in Systemic Juvenile Idiopathic Arthritis: Response Differs by Disease Duration at Medication Initiation and by Phenotype of Disease
Objective: We performed a single-center retrospective study to determine the different efficacy of tocilizumab (TCZ) in the early and late stages and in three phenotypic subgroups (monocyclic, polycyclic, and persistent) of systemic juvenile idiopathic arthritis (sJIA). Methods: Clinical and serolog...
Autores principales: | Yan, Xin, Tang, Wenjing, Zhang, Zhiyong, Zhang, Yu, Luo, Chong, Tang, Xuemei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606744/ https://www.ncbi.nlm.nih.gov/pubmed/34820342 http://dx.doi.org/10.3389/fped.2021.735846 |
Ejemplares similares
-
Multicentric Carpo-Tarsal Osteolysis Syndrome Mimicking Juvenile Idiopathic Arthritis: Two Case Reports and Review of the Literature
por: Wu, Junfeng, et al.
Publicado: (2021) -
Wilson’s Disease Masquerading as Juvenile Idiopathic Arthritis in an Adolescent
por: Goyal, Rajeev, et al.
Publicado: (2020) -
JAK inhibitors in systemic juvenile idiopathic arthritis
por: He, Tingyan, et al.
Publicado: (2023) -
Isolated Facet Joint Arthritis in Juvenile Idiopathic Arthritis
por: Martone, Giulia, et al.
Publicado: (2021) -
Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
por: Murakami, Miho, et al.
Publicado: (2012)